TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Phase II Trial Evaluating Activity and Tolerability of Fixed Dose of Oxycodone and Increasing Dose of Pregabalin Versus Increasing Dose of Oxycodone and Fixed Dose of Pregabalin for the Treatment of Oncological Neuropathic Pain
Brief Summary: The aim of the study is to assess tolerability and activity of oxycodone and pregabalin in combination for the treatment of oncological neuropathic pain with two different strategies.


Options:
A: Arm Label: Morphine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Morphine | Arm Label: Oxycodone; Type: EXPERIMENTAL; Interventions: Drug: Oxycodone | Arm Label: Buprenorphine; Type: EXPERIMENTAL; Interventions: Drug: Buprenorphine | Arm Label: Fentanyl; Type: EXPERIMENTAL; Interventions: Drug: Fentanyl | Intervention Type: DRUG; Name: Morphine; Assigned to Arm(s): Morphine | Intervention Type: DRUG; Name: Fentanyl; Assigned to Arm(s): Fentanyl | Intervention Type: DRUG; Name: Buprenorphine; Assigned to Arm(s): Buprenorphine | Intervention Type: DRUG; Name: Oxycodone; Assigned to Arm(s): Oxycodone
B: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: oxycodone, Drug: pregabalin | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: oxycodone, Drug: pregabalin | Intervention Type: DRUG; Name: oxycodone; Assigned to Arm(s): A, B | Intervention Type: DRUG; Name: pregabalin; Assigned to Arm(s): A, B
C: Arm Label: 001; Type: EXPERIMENTAL; Interventions: Drug: R331333 (referred to as JNS024 ER or CG5503) | Arm Label: 002; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oxycodone CR | Intervention Type: DRUG; Name: Oxycodone CR; Assigned to Arm(s): 002 | Intervention Type: DRUG; Name: R331333 (referred to as JNS024 ER or CG5503); Assigned to Arm(s): 001
D: Intervention Type: DRUG; Name: oxycodone fentanyl; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Efficacy of Cranberry Juice in the Prevention of Urinary Tract Infections in Children - Randomized, Placebo Controlled Multi-Center Study
Brief Summary: The objective of the study is to determine whether recurrences of urinary tract infection in children can be prevented with cranberry juice.


Options:
A: Arm Label: Cranberry-lingonberry juice; Type: EXPERIMENTAL; Interventions: Other: Cranberry-lingonberry juice | Arm Label: Placebo juice; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo juice | Intervention Type: OTHER; Name: Cranberry-lingonberry juice; Assigned to Arm(s): Cranberry-lingonberry juice | Intervention Type: OTHER; Name: Placebo juice; Assigned to Arm(s): Placebo juice
B: Arm Label: Cranberry; Type: EXPERIMENTAL; Interventions: Dietary Supplement: cranberry type A pro anthocyandines | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: cranberry type A pro anthocyandines; Assigned to Arm(s): Cranberry | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Biological: Cranberry juice | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo juice | Intervention Type: BIOLOGICAL; Name: Cranberry juice; Assigned to Arm(s): A | Intervention Type: BIOLOGICAL; Name: Placebo juice; Assigned to Arm(s): B
D: Arm Label: Arm 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cranberry juice cocktail | Arm Label: Arm 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cranberry juice cocktail | Arm Label: Arm 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Cranberry juice cocktail | Arm Label: Arm 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: Cranberry juice cocktail | Intervention Type: DRUG; Name: Cranberry juice cocktail; Assigned to Arm(s): Arm 1, Arm 2, Arm 3, Arm 4

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: International, Multicenter, Double-Blind, Placebo-Controlled, Randomized Phase I/II Trial of Desmoteplase in the Indication of Acute Ischemic Stroke
Brief Summary: The purpose of this study was to explore trends in safety and efficacy, and to find the optimal dose for the subsequent phase III trial. The decision to initiate the phase III trial will depend on both safety (incidence of symptomatic intracranial hemorrhage) and efficacy (reperfusion measured by MRI and correlating with clinical outcome) profiles. The safety (incidence of symptomatic intracranial haemorrhage) and efficacy (reperfusion measured by MRI and correlating with clinical outcome) profiles gained from this study were the basis of planning the phase III.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Desmoteplase | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Desmoteplase | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Desmoteplase; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Desmoteplase; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Desmoteplase | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Desmoteplase | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Desmoteplase | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Desmoteplase; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Desmoteplase; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Desmoteplase; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 4
C: Arm Label: Desmoteplase, low dose; Type: EXPERIMENTAL; Interventions: Drug: Desmoteplase | Arm Label: Desmoteplase, high dose; Type: EXPERIMENTAL; Interventions: Drug: Desmoteplase | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Desmoteplase; Assigned to Arm(s): Desmoteplase, low dose | Intervention Type: DRUG; Name: Desmoteplase; Assigned to Arm(s): Desmoteplase, high dose | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Ultrasound; Type: ACTIVE_COMPARATOR; Interventions: Other: Ultrasound | Arm Label: Sham ultrasound; Type: PLACEBO_COMPARATOR; Interventions: Other: Sham ultrasound | Intervention Type: OTHER; Name: Ultrasound; Assigned to Arm(s): Ultrasound | Intervention Type: OTHER; Name: Sham ultrasound; Assigned to Arm(s): Sham ultrasound

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: International, Multicenter, Double-Blind, Placebo-Controlled, Randomized Phase I/II Trial of Desmoteplase in the Indication of Acute Ischemic Stroke
Brief Summary: The purpose of this study was to explore trends in safety and efficacy, and to find the optimal dose for the subsequent phase III trial. The decision to initiate the phase III trial will depend on both safety (incidence of symptomatic intracranial hemorrhage) and efficacy (reperfusion measured by MRI and correlating with clinical outcome) profiles. The safety (incidence of symptomatic intracranial haemorrhage) and efficacy (reperfusion measured by MRI and correlating with clinical outcome) profiles gained from this study were the basis of planning the phase III.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Desmoteplase | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Desmoteplase | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Desmoteplase; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Desmoteplase; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3
B: Arm Label: Cerebrolysin; Type: EXPERIMENTAL; Interventions: Drug: Cerebrolysin | Arm Label: 0.9% Saline Solution; Type: PLACEBO_COMPARATOR; Interventions: Drug: 0.9% Saline Solution | Intervention Type: DRUG; Name: Cerebrolysin; Assigned to Arm(s): Cerebrolysin | Intervention Type: DRUG; Name: 0.9% Saline Solution; Assigned to Arm(s): 0.9% Saline Solution
C: Arm Label: IV tPA; Type: EXPERIMENTAL; Interventions: Drug: Tissue Plasminogen Activator (Alteplase) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Tissue Plasminogen Activator (Alteplase); Assigned to Arm(s): IV tPA | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Desmoteplase | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Desmoteplase | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Desmoteplase | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Desmoteplase; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Desmoteplase; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Desmoteplase; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 4

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase I/II Randomized, Double-Blind, Placebo-Controlled, Single-Dose, Dose Escalation Study of KB001 in Cystic Fibrosis Patients Infected With Pseudomonas Aeruginosa
Brief Summary: The primary objective of this study is to evaluate the safety and tolerability of a single dose of KB001 in Cystic Fibrosis patients infected with Pseudomonas aeruginosa (Pa)


Options:
A: Arm Label: Antioxidant-enriched multivitamin supplement; Type: EXPERIMENTAL; Interventions: Dietary Supplement: AquADEK | Intervention Type: DIETARY_SUPPLEMENT; Name: AquADEK; Assigned to Arm(s): Antioxidant-enriched multivitamin supplement
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Esomeprazole; Type: ACTIVE_COMPARATOR; Interventions: Drug: Esomeprazole | Intervention Type: DRUG; Name: Esomeprazole; Assigned to Arm(s): Esomeprazole | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: AquADEKs-2; Type: EXPERIMENTAL; Interventions: Drug: AquADEKs-2, Dietary Supplement: control multivitamin | Arm Label: Control multivitamin; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: control multivitamin | Intervention Type: DRUG; Name: AquADEKs-2; Assigned to Arm(s): AquADEKs-2 | Intervention Type: DIETARY_SUPPLEMENT; Name: control multivitamin; Assigned to Arm(s): AquADEKs-2, Control multivitamin
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Biological: KB001 | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: BIOLOGICAL; Name: KB001; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Use of Topical Budesonide in the Treatment of Eosinophilic Esophagitis, a Randomized Clinical Trial
Brief Summary: This study is designed to evaluate whether or not oral viscous budesonide is effective in treating children with Eosinophilic Esophagitis.


Options:
A: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: budesonide | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: budesonide | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Drug: budesonide | Intervention Type: DRUG; Name: budesonide; Assigned to Arm(s): 2, 3, 4 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 1
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Budesonide plus Prevacid | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo plus Prevacid | Intervention Type: DRUG; Name: Budesonide plus Prevacid; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo plus Prevacid; Assigned to Arm(s): 2
C: Arm Label: Oat Flour 600 mg; Type: PLACEBO_COMPARATOR; Interventions: Drug: Oat Flour | Arm Label: Peanut Protein 4,000mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Peanut Protein 4,000mg, Drug: Oat Flour | Arm Label: Peanut Protein 300 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oat Flour, Drug: Peanut Protein 300 mg | Intervention Type: DRUG; Name: Peanut Protein 4,000mg; Assigned to Arm(s): Peanut Protein 4,000mg | Intervention Type: DRUG; Name: Oat Flour; Assigned to Arm(s): Oat Flour 600 mg, Peanut Protein 300 mg, Peanut Protein 4,000mg | Intervention Type: DRUG; Name: Peanut Protein 300 mg; Assigned to Arm(s): Peanut Protein 300 mg
D: Arm Label: IV ABT-308 in asthmatics; Type: EXPERIMENTAL; Interventions: Drug: ABT-308, Drug: Placebo | Arm Label: SC ABT-308 in asthmatics; Type: EXPERIMENTAL; Interventions: Drug: ABT-308, Drug: Placebo | Arm Label: IV ABT-308 in healthy volunteers; Type: EXPERIMENTAL; Interventions: Drug: ABT-308, Drug: Placebo | Intervention Type: DRUG; Name: ABT-308; Assigned to Arm(s): IV ABT-308 in asthmatics, IV ABT-308 in healthy volunteers | Intervention Type: DRUG; Name: ABT-308; Assigned to Arm(s): SC ABT-308 in asthmatics | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): IV ABT-308 in asthmatics, IV ABT-308 in healthy volunteers | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): SC ABT-308 in asthmatics

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Training and Antioxidant Treatment on Circulating Markers of Oxidative Stress and Skeletal Muscle mRNA Expression
Brief Summary: The aim of the study is to compare the effects of an intensive 4 weeks exercise training program with or without additional treatment with antioxidants. 16 volunteers are included into the study and randomized into a treatment (n=8,Vitamine E 400 IU od + vitamine C 1g twice daily) and a non-treatment (n=8, training only) group. Before and after the training program, skeletal muscle biopsies will be taken to measure PGC-1alpha and PPARgamma mRNA expression. In addition before and after the training program individuals will have the following measurements: body weight, waist circumference, body fat content (DEXA scan), euglycemic-hyperinsulinemic clamps, ergospirometer (VO2 max), routine laboratory measurements, serum malondialdehyde concentrations.


Options:
A: Arm Label: 9 elite weightlifters; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Natural Pomegranate Juice | Arm Label: 9elite weightlifters; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo Juice | Intervention Type: DIETARY_SUPPLEMENT; Name: Natural Pomegranate Juice; Assigned to Arm(s): 9 elite weightlifters | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo Juice; Assigned to Arm(s): 9elite weightlifters
B: Arm Label: vitamins minerals; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Taking of blood, Dietary Supplement: needle biopsy of the vastus lateralis muscle, Dietary Supplement: Vit C Vit E Zn Se | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Procedure: Taking of blood, Dietary Supplement: needle biopsy of the vastus lateralis muscle, Dietary Supplement: Placebo Vit E Placebo Vit C Zn Se | Intervention Type: PROCEDURE; Name: Taking of blood; Assigned to Arm(s): Placebo, vitamins minerals | Intervention Type: DIETARY_SUPPLEMENT; Name: needle biopsy of the vastus lateralis muscle; Assigned to Arm(s): Placebo, vitamins minerals | Intervention Type: DIETARY_SUPPLEMENT; Name: Vit C Vit E Zn Se; Assigned to Arm(s): vitamins minerals | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo Vit E Placebo Vit C Zn Se; Assigned to Arm(s): Placebo
C: Arm Label: n-acetylcysteine/placebo supplementation; Type: EXPERIMENTAL; Interventions: Dietary Supplement: n-acetylcysteine supplementation | Intervention Type: DIETARY_SUPPLEMENT; Name: n-acetylcysteine supplementation; Assigned to Arm(s): n-acetylcysteine/placebo supplementation
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin C, Vitamin E | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Antioxidant treatment | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin C, Vitamin E; Assigned to Arm(s): 1 | Intervention Type: DIETARY_SUPPLEMENT; Name: Antioxidant treatment; Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Bifidobacterium Lactis BB12 and Xylitol Delivered With a Novel Slow-release Pacifier
Brief Summary: Aims:

1. To develop a food supplement containing a health-promoting probiotic bacteria (B. lactis BB12) and xylitol to be administered with a novel soft, possibly occlusion-friendly pacifier.
2. Test in a clinical study how feasible the method is and to study how the intervention affects caries occurrence.

Main hypothesis:

The administration of B. lactis BB12 and xylitol affects beneficially the dental health of the child.


Options:
A: Arm Label: A, observation; Type: EXPERIMENTAL; Interventions: Dietary Supplement: A, erythritol | Arm Label: B; Type: EXPERIMENTAL; Interventions: Dietary Supplement: xylitol | Arm Label: C; Type: EXPERIMENTAL; Interventions: Dietary Supplement: C, sorbitol | Intervention Type: DIETARY_SUPPLEMENT; Name: A, erythritol; Assigned to Arm(s): A, observation | Intervention Type: DIETARY_SUPPLEMENT; Name: xylitol; Assigned to Arm(s): B | Intervention Type: DIETARY_SUPPLEMENT; Name: C, sorbitol; Assigned to Arm(s): C
B: Arm Label: xylitol lozenge; Type: EXPERIMENTAL; Interventions: Dietary Supplement: xylitol | Arm Label: inactive lozenge; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: inactive lozenge | Intervention Type: DIETARY_SUPPLEMENT; Name: xylitol; Assigned to Arm(s): xylitol lozenge | Intervention Type: DIETARY_SUPPLEMENT; Name: inactive lozenge; Assigned to Arm(s): inactive lozenge
C: Arm Label: xylitol wipe; Type: EXPERIMENTAL; Interventions: Dietary Supplement: xylitol wipe | Arm Label: placebo wipe; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: placebo wipe | Intervention Type: DIETARY_SUPPLEMENT; Name: xylitol wipe; Assigned to Arm(s): xylitol wipe | Intervention Type: DIETARY_SUPPLEMENT; Name: placebo wipe; Assigned to Arm(s): placebo wipe
D: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Sorbitol | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Xylitol | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Xylitol + BB12 | Intervention Type: DIETARY_SUPPLEMENT; Name: Sorbitol; Assigned to Arm(s): 1 | Intervention Type: DIETARY_SUPPLEMENT; Name: Xylitol + BB12; Assigned to Arm(s): 3 | Intervention Type: DIETARY_SUPPLEMENT; Name: Xylitol; Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effectiveness of Physiotherapy for Vertebral Osteoporotic Fracture: a Randomised Controlled Pilot Trial
Brief Summary: The aim of this pilot study was to determine the effect of physiotherapy on impairments and health-related quality of life in people with a painful osteoporotic spinal fracture. It is hypothesised that physiotherapy will reduce impairments and improve quality of life in this patient group.


Options:
A: Arm Label: Exercise and advise to stay active; Type: ACTIVE_COMPARATOR; Interventions: Other: Exercise | Arm Label: Rest and use of flexible lumbar belt; Type: EXPERIMENTAL; Interventions: Other: Restitution | Intervention Type: OTHER; Name: Exercise; Assigned to Arm(s): Exercise and advise to stay active | Intervention Type: OTHER; Name: Restitution; Assigned to Arm(s): Rest and use of flexible lumbar belt
B: Arm Label: Physiotherapy; Type: ACTIVE_COMPARATOR; Interventions: Other: Physiotherapy | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Physiotherapy; Assigned to Arm(s): Physiotherapy
C: Arm Label: Physical Activity; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Physical Activity | Arm Label: Successful Aging; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Successful Aging | Intervention Type: BEHAVIORAL; Name: Physical Activity; Assigned to Arm(s): Physical Activity | Intervention Type: BEHAVIORAL; Name: Successful Aging; Assigned to Arm(s): Successful Aging
D: Arm Label: Spinal orthosis group; Type: ACTIVE_COMPARATOR; Interventions: Device: Spinal orthosis Spinomed | Arm Label: Equipment training group; Type: ACTIVE_COMPARATOR; Interventions: Other: Equipment training | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Spinal orthosis Spinomed; Assigned to Arm(s): Spinal orthosis group | Intervention Type: OTHER; Name: Equipment training; Assigned to Arm(s): Equipment training group

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multicentre, Multinational, Double-Blind, Placebo-Controlled, Randomised Phase II Trial of Desmoteplase (INN) in the Indication of Acute Ischaemic Stroke
Brief Summary: The DIAS study (Part 2) was performed to support the dose finding of desmoteplase treatment in subjects with acute ischemic stroke selected by perfusion/diffusion mismatch on MRI within a time window of 3 to 9 h after stroke-symptom onset. In addition, it assessed safety and tolerability of 3 doses of desmoteplase compared with placebo with special consideration of intracranial hemorrhage and major systemic bleedings.


Options:
A: Arm Label: Desmoteplase, low dose; Type: EXPERIMENTAL; Interventions: Drug: Desmoteplase | Arm Label: Desmoteplase, high dose; Type: EXPERIMENTAL; Interventions: Drug: Desmoteplase | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Desmoteplase; Assigned to Arm(s): Desmoteplase, low dose | Intervention Type: DRUG; Name: Desmoteplase; Assigned to Arm(s): Desmoteplase, high dose | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Desmoteplase | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Desmoteplase | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Desmoteplase; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Desmoteplase; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Desmoteplase | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Desmoteplase | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Desmoteplase | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Desmoteplase; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Desmoteplase; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Desmoteplase; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 4
D: Arm Label: Ultrasound; Type: ACTIVE_COMPARATOR; Interventions: Other: Ultrasound | Arm Label: Sham ultrasound; Type: PLACEBO_COMPARATOR; Interventions: Other: Sham ultrasound | Intervention Type: OTHER; Name: Ultrasound; Assigned to Arm(s): Ultrasound | Intervention Type: OTHER; Name: Sham ultrasound; Assigned to Arm(s): Sham ultrasound

Answer: C